Plain-English translation of NCT05731726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an immunotherapy drug, combined with chemotherapy (CAPEOX) and an anti-inflammatory pill () as a pre-surgery treatment for locally advanced rectal cancer. The study focuses on patients whose tumors are less responsive to immunotherapy alone. Researchers hope this three-part combination approach will shrink tumors more effectively before surgery.
Most colorectal cancers don't respond well to immunotherapy alone. This medication aims to work better when paired with chemotherapy and an anti-inflammatory drug, potentially improving treatment outcomes for patients who currently have fewer effective options.
You likely qualify if…
You likely don't qualify if…
Over 12 to 24 weeks, you would receive the medication combination through intravenous infusion and oral pills, with treatment repeating every 3 weeks for 4 to 8 cycles. After completing the medication cycles, you would have surgery to remove the tumor. You would have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China